BioMarin Reports Encouraging Data In Hemophilia A Gene Therapy Program

BioMarin Pharmaceutical Inc. (BMRN) announced encouraging preliminary data from an ongoing Phase 1/2 clinical trial with BMN 270, an investigational gene therapy treatment for hemophilia A.

from RTT - Biotech http://ift.tt/1Sv7nxn
via IFTTT